KRAS and lung cancer: As observed in the HER2+ breast cancer and Kras-driven lung cancer models [29,30], MSU-42011 (~43%, p = 0.0246) and selumetinib (~43%, p = 0.0175) alone or in combination (~57%, p = 0.0016) reduced the expression of FOXP3+ in the flank tumors of MPNST compared with vehicle treatment.